Abstract
Abstract only
- Title
- AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results
- Creators
- Ignace Vergote - KU LeuvenLars Christian Hanker - University Hospital Schleswig-HolsteinAnne Floquet - Institut BergoniéJoern Rau - Philipps University of MarburgJae-Weon Kim - Seoul National UniversityEugenia Ortega Izquierdo - Hospital Miguel Servet, Zaragoza, SpainMichael Friedlander - Prince of Wales HospitalSandro Pignata - Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Keiichi Fujiwara - Saitama Medical UniversityNicoletta Colombo - European Institute of OncologyMansoor Raza Mirza - Copenhagen University HospitalBradley J. Monk - Dignity HealthManfred Mörtl - Klinikum KlagenfurtPaula Calvert - University Hospital WaterfordThomas J. Herzog - University of CincinnatiChristian Jackisch - Sana Klinikum OffenbachJérome Meunier - Centre hospitalier régional d'OrléansJung-Yun Lee - Yonsei UniversityAntje Kristina Belau - University of GreifswaldAndreas Du Bois - Kliniken Essen-Mitte
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.5518-5518
- Identifiers
- 991005968874302656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article